Last updated: March 2026
LGD-3303 is a non-steroidal androgen receptor agonist from Ligand Pharmaceuticals — the same company that developed LGD-4033. Considered more potent and more suppressive than its predecessor, LGD-3303 carries a higher risk profile with limited human research data. All efficacy data from animal models only.
LGD-3303 is a full non-steroidal androgen receptor agonist. Unlike partial agonists like ACP-105, it fully activates the androgen receptor — translating to greater anabolic effect but also greater HPG axis suppression and androgenic activity in non-target tissues.
LGD-3303 fully activates the androgen receptor, similar to testosterone but without the steroidal structure. Full agonism delivers maximal anabolic signaling in muscle and bone — resulting in superior mass and strength effects in animal models compared to partial agonists. This comes with proportionally higher suppression risk.
In castrated rat models, LGD-3303 demonstrated strong preservation and growth of skeletal muscle mass, as well as significant bone density support. Its anabolic potency in animal models is among the highest in the non-steroidal SARM class. These effects make it a research candidate for severe muscle wasting conditions.
As a full AR agonist that reaches systemic circulation, LGD-3303 strongly suppresses the hypothalamic-pituitary-gonadal axis. LH and FSH levels are suppressed dose-dependently in animal models. Endogenous testosterone production falls significantly. Post-cycle recovery protocols are a significant consideration.
Unlike some research compounds with poor oral absorption, LGD-3303 demonstrates good oral bioavailability in animal studies. This makes it genuinely usable as an oral compound, unlike SR-9009. However, this also means stronger systemic effects and suppression compared to compounds with lower oral absorption.
⚠️ All data below is from animal studies (rodent models). No approved human clinical trials exist for LGD-3303. Data is for research reference only.
Essential monitoring supplies given LGD-3303's higher suppression profile.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. LGD-3303 is not FDA approved and is not intended for human use. All efficacy data is from preclinical animal studies. Given its high suppression profile, this compound carries significant risk. Do not use any research chemical without consulting a qualified medical professional.